FDA approves Q-Med's Deflux for VUR (vesicoureteral reflux):
This article was originally published in Clinica
Executive Summary
The US FDA has approved for sale Q-Med's injectable Deflux implant for treating vesicoureteral reflux (VUR) in children. VUR is a condition that leads to urine leakage from the urinary bladder back into the kidneys and which can, in the long-term, result in irreversible kidney damage. Consisting of NASHA (non-animal stabilised hyaluronic acid) and dextranomer, Deflux is the first endoscopic treatment for VUR to be approved by the FDA, claims Q-Med, of Uppsala, Sweden. The firm estimates that the US market for the product is worth $30 million annually. Deflux is already sold in over 10 markets, mainly in Europe.